Possibilities of immunocorrection in COVID-19 therapy of patients on an outpatient basis
DOI: 10.32364/2587-6821-2021-5-7-468-472
L.R. Mukhamadieva1, G.A. Mavzyutova2, G.Kh. Mirsayeva2, G.M. Khasanova2, G.A. Galieva2, G.M. Abdrakhmanova 2, A.A. Safina3
1Megi Clinic, Ufa, Russian Federation
2Bashkir State Medical University, Ufa, Russian Federation
3City Clinical Hospital of the Demsky District, Ufa, Russian Federation
Aim: to evaluate the clinical efficacy of azoximer bromide inclusion in the complex therapy of patients with a confirmed diagnosis of COVID-19 (moderate degree) who were receiving treatment on an outpatient basis.
Patients and Methods: data from medical records of 100 patients who were treated in outpatient clinics for COVID-19 in Ufa (June–November 2020) were retrospectively evaluated. There were 2 groups of 50 patients: the main group receiving azoximer bromide and the comparison group receiving only standard therapy. The criteria for evaluating the therapy efficacy were the dynamics of the disease clinical picture, laboratory parameters characterizing inflammation.
Results: in the main group, the relief of complaints and a significant condition improvement according to physical examination were recorded significantly earlier — after 9.68±5.23 days versus 13.00±4.95 days in the comparison group (p=0.0012). The period of body temperature normalization in patients receiving immunomodulatory therapy was 7.20±1.41 days, which is significantly less than in patients receiving standard therapy — 16.20±2.74 days (p=0.0001). When contacting the outpatient clinic, all patients had an increase in the level of C-reactive protein: in the main group — up to 13.91±17.28 mg/L, in the comparison group — up to 12.22±8.32 mg/L (p=0.71). The result of therapy was a decrease in this indicator to 6.28±5.06 mg/L and 4.44±3.73 mg/L, respectively (p=0.0314). On the 17th day after the treatment initiation, all patients had antibodies (IgM and IgG) to SARS-CoV-2.
Conclusions: azoximer bromide inclusion in the complex therapy of patients with COVID-19 allows for faster normalization of the patients’ condition, is not accompanied by adverse events and can be considered as a pathogenetic therapy variant of patients with COVID-19 with a predominantly severe course in the setting of concomitant diseases.
Keywords: coronavirus infection, SARS-CoV-2, COVID-19, pneumonia, immunocorrection, pathogenetic therapy, azoximer bromide.
For citation: Mukhamadieva L.R., Mavzyutova G.A., Mirsayeva G.Kh. et al. Possibilities of immunocorrection in COVID-19 therapy of patients on an outpatient basis. Russian Medical Inquiry. 2021;5(7):468–472 (in Russ.). DOI: 10.32364/2587-6821-2021-5-7-468-472.
2. Feng Y., Ling Y., Bai T. et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. DOI: 10.1164/rccm.202002-0445OC.
3. Teijaro J.R., Walsh K.B., Rice S. et al. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci USA. 2014;111(10): 3799–3804. DOI: 10.1073/pnas.1400593111.
4. Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.
5. Kostinov M.P. Immunopathogenic properties of SARS-CoV2 as a basis for the choice of pathogenetic therapy. Immunologiya. 2020;41(1):83–90 (in Russ.). DOI: 10.33029/0206-4952-2020-41-1-83-91.
6. Remy K.E., Brakenridge S.C., Francois B. et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020;8(10):946–949. DOI: 10.1016/S2213-2600(20)30217-4.
7. Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. DOI: 10.1002/jmv.26232.
8. Vyšetrovací algoritmus a medikamentózna liečba pacientov nad 65 rokov, pacientov so závažným priebehom a polymorbídnych pacientovpočas hospitalizácie na infekčnom oddelení (Electronic resource.) URL: https://standardnepostupy.sk/_files/200000421–45c4245c44/COVID-19%20 hospitalizovan%C3%AD%20pacientiv%20nad%2065%20rokov%20-%20 lie%C4%8Dba%20-%20infekcne%20oddelenia%20verzia%202.0.pdf. (access date: 07.07.2021).
9. Mavzyutova G.A., Mukhamadieva L.R., Fazlyeva R.M. et al. Rational immunocorrection in the complex therapy of community-acquired pneumonia. Medical Council. 2015;16:68–73 (in Russ.).
10. Karaulov A.V., Mavzyutova G.A., Fazlyeva R.M. et al. Clinical and immunological features of community-acquired pneumonia. In: Immunocorrection. Ufa, 2010 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
